期刊
INTERNATIONAL JOURNAL OF CANCER
卷 135, 期 10, 页码 2262-2272出版社
WILEY
DOI: 10.1002/ijc.29081
关键词
retinoic acid; leukemia; differentiation; degradation
类别
资金
- The Ligue Nationale contre le Cancer
- The Institut National de la Sante et de la Recherche Medicale (INSERM)
- The Centre National de la Recherche Scientifique (CNRS)
- University Paris Diderot
- Institut Universitaire de France
- Institut National du Cancer
- The Association pour la Recherche contre le Cancer (ARC) (Prix Griffuel)
- The European Research Council [268729]
- European Research Council (ERC) [268729] Funding Source: European Research Council (ERC)
Inevitably fatal some 40 years, acute promyelocytic leukemia (APL) can now be cured in more than 95% of cases. This clinical success story is tightly linked to tremendous progress in our understanding of retinoic acid (RA) signaling. The discovery of retinoic acid receptor alpha (RARA) was followed by the cloning of the chromosomal translocations driving APL, all of which involve RARA. Since then, new findings on the biology of nuclear receptors have progressively enlightened the basis for the clinical efficacy of RA in APL. Reciprocally, the disease offered a range of angles to approach the cellular and molecular mechanisms of RA action. This virtuous circle contributed to make APL one of the best-understood cancers from both clinical and biological standpoints. Yet, some important questions remain unanswered including how lessons learnt from RA-triggered APL cure can help design new therapies for other malignancies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据